Topcon Healthcare announced a strategic investment in Senseye, a US-based innovator developing the first mental health diagnostic platform powered by ocular biomarkers.
Senseye technology uses AI and computer vision to analyze ocular metrics such as pupil dynamics and eye movement, captured via a smartphone camera. The data are translated into validated digital biomarkers to support diagnosis and monitoring of Post-Traumatic Stress Disorder (PTSD), Major Depressive Disorder (MDD), and Generalized Anxiety Disorder (GAD).
Expanding “Healthcare from the Eye” Into Mental Health
This is Topcon Healthcare’s first investment in technology for mental health and neuropsychiatry. Leveraging the eye as a non-invasive window into the brain, Senseye technology supports Topcon’s Healthcare from the Eye initiative to facilitate early detection of debilitating, chronic diseases enabling earlier, more effective, and less costly interventions.
Unlike traditional approaches which rely on subjective questionnaires, the Senseye solution offers an objective, scalable, and non-invasive method for mental health assessment. It will enable primary care physicians to incorporate objective mental health screening into routine exams, particularly in underserved settings where behavioral health specialists are scarce. This technology will also allow eye care providers to identify and flag potential neuropsychiatric concerns during routine eye exams and refer patients as needed to primary care for additional evaluation.
“Senseye is breaking new ground by providing objective, measurable mental health assessments from the eye,” said Ali Tafreshi, CEO & President of Topcon Healthcare. “Their work exemplifies our Healthcare from the Eye vision, expanding the role of ocular data beyond eye and systemic disease into psychiatry. We are proud to support Senseye in accelerating their mission and see exciting opportunities for future collaboration.”
With this strategic move, Topcon Healthcare continues to redefine the application of ocular data for assessment of eye disease, systemic disorders, and now psychiatric conditions for broader healthcare impact. As global demand for mental health solutions increases, this partnership represents a pivotal step in transforming how mental health is screened, diagnosed, and managed.
“Topcon Healthcare’s investment is more than capital, it is validation from a global leader in digital health technology that the eye holds the key to understanding the brain and mind,” said David Zakariaie, Founder & CEO, Senseye. “Together, we can bring objectivity, accessibility, and trust to mental health diagnostics worldwide.”
This collaboration lays the groundwork for new diagnostic modules within Harmony, Topcon Healthcare’s connected care platform, which already integrates imaging, AI analytics, and data sharing across clinical settings. By embedding Senseye’s technology into Harmony, Topcon aims to provide clinicians with a more holistic understanding of each patient’s mental and physical health status, captured through the eye.
